Abstract
Class III β-tubulin (TUBB3) is a prominent mechanism of drug resistance expressed in a variety of solid tumors and particularly in lung and ovarian cancer. In the classical view, TUBB3 expression and drug resistance have been linked, and together they have been associated with a perturbation in microtubule dynamics. In keeping with this observation, TUBB3 was associated with drug resistance only when chemotherapy included a taxane in its chemical composition. In this review, we demonstrate that the classical supposition about TUBB3 is not correct, and that instead TUBB3 expression is linked to drug resistance as a complex survival mechanism activated by microenvironmental conditions such as poor nutrient supply and hypoxia.
Keywords: Tubulin, biomarkers, drug-resistance, poor outcome, pharmacogenomics, toxicity, biomediators, myeloid leukemia, tumors, imatinib, dasatinib, nilotinib, oncogene, carcinoma, angiogenesis
Current Molecular Medicine
Title: Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?
Volume: 11 Issue: 9
Author(s): M. Mariani, S. Shahabi, S. Sieber, G. Scambia and C. Ferlini
Affiliation:
Keywords: Tubulin, biomarkers, drug-resistance, poor outcome, pharmacogenomics, toxicity, biomediators, myeloid leukemia, tumors, imatinib, dasatinib, nilotinib, oncogene, carcinoma, angiogenesis
Abstract: Class III β-tubulin (TUBB3) is a prominent mechanism of drug resistance expressed in a variety of solid tumors and particularly in lung and ovarian cancer. In the classical view, TUBB3 expression and drug resistance have been linked, and together they have been associated with a perturbation in microtubule dynamics. In keeping with this observation, TUBB3 was associated with drug resistance only when chemotherapy included a taxane in its chemical composition. In this review, we demonstrate that the classical supposition about TUBB3 is not correct, and that instead TUBB3 expression is linked to drug resistance as a complex survival mechanism activated by microenvironmental conditions such as poor nutrient supply and hypoxia.
Export Options
About this article
Cite this article as:
Mariani M., Shahabi S., Sieber S., Scambia G. and Ferlini C., Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?, Current Molecular Medicine 2011; 11 (9) . https://dx.doi.org/10.2174/156652411798062368
| DOI https://dx.doi.org/10.2174/156652411798062368 |
Print ISSN 1566-5240 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Recent Patents of Gene Sequences Relative to the Phosphatidylinositol 3-kinase / Akt Pathway and their Relevance to Drug Discovery
Recent Patents on DNA & Gene Sequences A Closer Look at Protein Transduction Domains as a Tool in Drug Delivery
Current Nanoscience Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Current Pharmaceutical Design Heat Shock Proteins: A Potential Anticancer Target
Current Drug Targets Regulation of Cell Migration and Invasion by Specific Modules of uPA: Mechanistic Insights and Specific Inhibitors
Current Drug Targets Nanostructures for Bypassing Blood Brain Barrier
Current Bioactive Compounds Nanoparticulate Drug Delivery Sytem for Cancer Therapy: Oppourtunities and Challenges
Recent Patents on Nanomedicine Rheumatoid Nodules and Lung
Current Respiratory Medicine Reviews Tumor Specific Novel Taxoid-Monoclonal Antibody Conjugates
Current Medicinal Chemistry Molecular Classification and Drug Response Prediction in Cancer
Current Drug Targets Antioxidant Effect of Mangiferin and its Potential to be a Cancer Chemoprevention Agent
Letters in Drug Design & Discovery Clinical and <i>In Silico</i> Outcomes of the Expression of miR-130a-5p and miR-615-3p in Tumor Compared with Non-Tumor Adjacent Tissues of Patients with BC
Anti-Cancer Agents in Medicinal Chemistry Gold Nanoparticles in Cancer Therapy: Efficacy, Biodistribution, and Toxicity
Current Pharmaceutical Design E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research Synthesis and Cytotoxic Activities of Difluoro-Dimethoxy Chalcones
Anti-Cancer Agents in Medicinal Chemistry Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry Cathelicidins: Peptides with Antimicrobial, Immunomodulatory, Anti- Inflammatory, Angiogenic, Anticancer and Procancer Activities
Current Protein & Peptide Science

